KRAS and neoplasm: Moreover, Park et al. indicated G12D/V KRAS mutation was consistently associated with less tumor infiltrating lymphocytes (TIL) infiltration and shorter recurrence free survival (RFS) in stage III CRC patients treated with adjuvant FOLFOX therapy [4].